Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | RGS12 | O14924 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RBP4 | P02753 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 2/20 | 0.30 |
| ▸ | MMP13 | P45452 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3501182 | 0.77 | TSHR (0.44) | TSHRRGS12GAARBP4HSD17B10 | |
| SCHEMBL2064738 | 0.75 | TSHR (0.42) | TSHRRGS12GAARBP4HSD17B10 | |
| SCHEMBL11628675 | 0.73 | TSHR (0.46) | TSHRRGS12GAARBP4HSD17B10 | |
| SCHEMBL10677331 | 0.73 | TSHR (0.50) | TSHRRGS12GAARBP4HSD17B10 | |
| SCHEMBL2184430 | 0.73 | TSHR (0.50) | TSHRRGS12GAARBP4HSD17B10 | |
| SCHEMBL16597493 | 0.71 | TSHR (0.44) | TSHRRGS12GAARBP4HSD17B10 | |
| Potassium Ion SCHEMBL16597641 | 0.71 | TSHR (0.44) | TSHRRGS12GAARBP4HSD17B10 | |
| SCHEMBL16597743 | 0.71 | TSHR (0.44) | TSHRRGS12GAARBP4HSD17B10 | |
| SCHEMBL5916254 | 0.71 | TSHR (0.39) | TSHRRGS12GAARBP4HSD17B10 | |
| SCHEMBL16597486 | 0.71 | TSHR (0.44) | TSHRRGS12GAARBP4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338471-B2 | (2,5-dioxoimidazolidin-i-yl)-n-hydroxy-acetamides as metalloproteinase inhibitors | MEDIVIR AB (SE) | 2012-12-25 | — | — | US | disclosed |
| US-20120015994-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MEDIVIR AB (SE) | 2012-01-19 | — | — | US | disclosed |
| US-8022092-B2 | (2,5-dioxoimidazolidin-1-yl)-N-hydroxy-acetamides as metalloproteinase inhibitors | MEDIVIR AB (SE) | 2011-09-20 | — | — | US | disclosed |
| US-20090215846-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MEDIVIR AB (SE) | 2009-08-27 | — | — | US | disclosed |
| EP-1966153-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | Medivir AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007068474-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MEDIVIR AB (SE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015994-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MMP12, MMP13, MMP14 | TSHR 4332/4885RGS12 337/4885GAA 306/4885 |
| US-20090215846-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MMP12, MMP13, MMP14 | TSHR 4332/4885RGS12 337/4885GAA 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.